{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:54:10Z","timestamp":1793231650847,"version":"4.5.0"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["ID1047824"],"award-info":[{"award-number":["ID1047824"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["ID1071659"],"award-info":[{"award-number":["ID1071659"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.antiviral.2019.04.001","type":"journal-article","created":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T21:32:35Z","timestamp":1554240755000},"page":"89-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["New antiviral approaches for human parainfluenza: Inhibiting the haemagglutinin-neuraminidase"],"prefix":"10.1016","volume":"167","author":[{"given":"Vimbaishe P.","family":"Chibanga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Dirr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Guillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim M.","family":"El-Deeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Bailly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin J.","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"von Itzstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2019.04.001_bib1","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1128\/AAC.49.1.398-405.2005","article-title":"The novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae","volume":"49","author":"Alymova","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.04.001_bib2","doi-asserted-by":"crossref","first-page":"8400","DOI":"10.1128\/JVI.00474-08","article-title":"Loss of the N-linked glycan at residue 173 of human parainfluenza virus type 1 hemagglutinin-neuraminidase exposes a second receptor-binding site","volume":"82","author":"Alymova","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.04.001_bib3","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1128\/AAC.48.5.1495-1502.2004","article-title":"Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo","volume":"48","author":"Alymova","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.04.001_bib4","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3851\/IMP1420","article-title":"Efficacy of the novel parainfluenza virus haemagglutinin-neuraminidase inhibitor BCX 2798 in mice - further evaluation","volume":"14","author":"Alymova","year":"2009","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2019.04.001_bib5","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1007\/s00705-018-3814-x","article-title":"Taxonomy of the order Mononegavirales: update 2018","volume":"163","author":"Amarasinghe","year":"2018","journal-title":"Arch. Virol."},{"key":"10.1016\/j.antiviral.2019.04.001_bib6","doi-asserted-by":"crossref","first-page":"8341","DOI":"10.1128\/JVI.00718-07","article-title":"Human parainfluenza viruses hPIV1 and hPIV3 bind oligosaccharides with alpha2-3-linked sialic acids that are distinct from those bound by H5 avian influenza virus hemagglutinin","volume":"81","author":"Amonsen","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.04.001_bib7","doi-asserted-by":"crossref","first-page":"24138","DOI":"10.1038\/srep24138","article-title":"A dual drug regimen synergistically blocks human parainfluenza virus infection","volume":"6","author":"Bailly","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2019.04.001_bib8","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1128\/JVI.01297-10","article-title":"The C proteins of human parainfluenza virus type 1 limit double-stranded RNA accumulation that would otherwise trigger activation of MDA5 and protein kinase R","volume":"85","author":"Boonyaratanakornkit","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.04.001_bib9","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1002\/anie.201309675","article-title":"Tuning mechanism\u2010based inactivators of neuraminidases: mechanistic and structural insights","volume":"53","author":"Buchini","year":"2014","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.antiviral.2019.04.001_bib10","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3390\/v4040613","article-title":"Paramyxovirus fusion and entry: multiple paths to a common end","volume":"4","author":"Chang","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2019.04.001_bib11","article-title":"1715. A randomized, double-blind, placebo-controlled multicenter phase 2 trial to examine the effects of DAS181 in immunocompromised (IC) patients with parainfluenza virus (PIV) lower respiratory tract infection (LRTI) on supplemental oxygen (SO)","volume":"vol. S50-S51","author":"Chemaly","year":"2018"},{"key":"10.1016\/j.antiviral.2019.04.001_bib12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.virusres.2013.03.012","article-title":"Role of N-linked glycosylation of the human parainfluenza virus type 3 hemagglutinin-neuraminidase protein","volume":"174","author":"Chu","year":"2013","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2019.04.001_bib13","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1128\/jvi.67.6.2972-2980.1993","article-title":"Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase","volume":"67","author":"Colman","year":"1993","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.04.001_bib14","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/81002","article-title":"Crystal structure of the multifunctional paramyxovirus hemagglutinin-neuraminidase","volume":"7","author":"Crennell","year":"2000","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.antiviral.2019.04.001_bib15","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/8503275","article-title":"DAS181 treatment of severe parainfluenza virus 3 pneumonia in allogeneic hematopoietic stem cell transplant recipients requiring mechanical ventilation","author":"Dhakal","year":"2016","journal-title":"Case Rep. Med."},{"key":"10.1016\/j.antiviral.2019.04.001_bib16","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1038\/s41598-017-04656-y","article-title":"The impact of the butterfly effect on human parainfluenza virus haemagglutinin-neuraminidase inhibitor design","volume":"7","author":"Dirr","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2019.04.001_bib17","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1002\/anie.201412243","article-title":"The catalytic mechanism of human parainfluenza virus type 3 haemagglutinin-neuraminidase revealed","volume":"54","author":"Dirr","year":"2015","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.antiviral.2019.04.001_bib18","doi-asserted-by":"crossref","first-page":"7613","DOI":"10.1021\/jm500759v","article-title":"Exploring human parainfluenza virus type-1 hemagglutinin-neuraminidase as a target for inhibitor discovery","volume":"57","author":"El-Deeb","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.04.001_bib19","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1039\/C6MD00519E","article-title":"Exploring inhibitor structural features required to engage the 216-loop of human parainfluenza virus type-3 hemagglutinin-neuraminidase","volume":"8","author":"El-Deeb","year":"2017","journal-title":"Med. Chem. Comm."},{"key":"10.1016\/j.antiviral.2019.04.001_bib20","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1099\/0022-1317-74-12-2781","article-title":"Comparative analysis of the immunoprotective abilities of glycosylated and deglycosylated parainfluenza virus type 3 surface glycoproteins","volume":"74","author":"Ewasyshyn","year":"1993","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2019.04.001_bib21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/IDR.S25874","article-title":"Current management of parainfluenza pneumonitis in immunocompromised patients: a review","volume":"5","author":"Falsey","year":"2012","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.antiviral.2019.04.001_bib22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0042-6822(91)90120-Z","article-title":"Glycosylation of the hemagglutinin-neuraminidase glycoprotein of human parainfluenza virus type 1 affects its functional but not its antigenic properties","volume":"183","author":"Gorman","year":"1991","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2019.04.001_bib23","doi-asserted-by":"crossref","first-page":"11108","DOI":"10.1128\/JVI.74.23.11108-11114.2000","article-title":"The anti-influenza virus agent 4-GU-DANA (zanamivir) inhibits cell fusion mediated by human parainfluenza virus and influenza virus HA","volume":"74","author":"Greengard","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.04.001_bib24","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1038\/ncomms6268","article-title":"Structure-guided discovery of potent and dual-acting human parainfluenza virus haemagglutinin\u2013neuraminidase inhibitors","volume":"5","author":"Guillon","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2019.04.001_bib25","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1399-3062.2012.00718.x","article-title":"Clinical potential of DAS181 for treatment of parainfluenza-3 infections in transplant recipients","volume":"14","author":"Guzman-Suarez","year":"2012","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.04.001_bib26","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1056\/NEJM200106213442507","article-title":"Respiratory syncytial virus and parainfluenza virus","volume":"344","author":"Hall","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2019.04.001_bib27","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1128\/CMR.16.2.242-264.2003","article-title":"Parainfluenza viruses","volume":"16","author":"Henrickson","year":"2003","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2019.04.001_bib28","doi-asserted-by":"crossref","first-page":"11792","DOI":"10.1128\/JVI.74.24.11792-11799.2000","article-title":"Mechanism of interference mediated by human parainfluenza virus type 3 infection","volume":"74","author":"Horga","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.04.001_bib29","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1006\/viro.1995.9925","article-title":"Hemagglutinin\u2013Neuraminidase of human parainfluenza 3: role of the neuraminidase in the viral life cycle","volume":"214","author":"Huberman","year":"1995","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2019.04.001_bib30","doi-asserted-by":"crossref","first-page":"7893","DOI":"10.1016\/j.bmc.2006.07.045","article-title":"2-Deoxy-2, 3-didehydro-N-acetylneuraminic acid analogues structurally modified at the C-4 position: synthesis and biological evaluation as inhibitors of human parainfluenza virus type 1","volume":"14","author":"Ikeda","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.04.001_bib31","doi-asserted-by":"crossref","first-page":"6783","DOI":"10.1016\/j.bmc.2008.05.055","article-title":"2-Deoxy-2, 3-didehydro-N-acetylneuraminic acid analogs structurally modified by thiocarbamoylalkyl groups at the C-4 position: synthesis and biological evaluation as inhibitors of human parainfluenza virus type 1","volume":"16","author":"Ikeda","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.04.001_bib32","first-page":"2","article-title":"Antiviral drug resistance as an adaptive process","author":"Irwin","year":"2016","journal-title":"Virus Evol."},{"key":"10.1016\/j.antiviral.2019.04.001_bib33","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.antiviral.2013.09.014","article-title":"Inhibition of primary clinical isolates of human parainfluenza virus by DAS181 in cell culture and in a cotton rat model","volume":"100","author":"Jones","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.04.001_bib34","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1021\/ja963036t","article-title":"Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active Site:\u2009 design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity","volume":"119","author":"Kim","year":"1997","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.antiviral.2019.04.001_bib35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1126\/science.1232552","article-title":"Mechanism-Based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activity","volume":"340","author":"Kim","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2019.04.001_bib36","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.jmb.2003.11.032","article-title":"Structure of the haemagglutinin-neuraminidase from human parainfluenza virus type III","volume":"335","author":"Lawrence","year":"2004","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.antiviral.2019.04.001_bib37","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1128\/AAC.42.3.647","article-title":"Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071","volume":"42","author":"Li","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.04.001_bib38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1006\/viro.1995.1564","article-title":"Cooperative neuraminidase activity in a paramyxovirus","volume":"213","author":"Mahon","year":"1995","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2019.04.001_bib39","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1128\/AAC.50.4.1470-1479.2006","article-title":"Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection","volume":"50","author":"Malakhov","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.04.001_bib40","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/0042-6822(81)90635-8","article-title":"Inhibition of the neuraminidase of paramyxoviruses by halide ions: a possible means of modulating the two activities of the HN protein","volume":"112","author":"Merz","year":"1981","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2019.04.001_bib41","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1128\/JVI.02331-09","article-title":"N-linked glycan at residue 523 of human parainfluenza virus type 3 hemagglutinin-neuraminidase masks a second receptor-binding site","volume":"84","author":"Mishin","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.04.001_bib42","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1172\/JCI25669","article-title":"Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease","volume":"115","author":"Moscona","year":"2005","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.antiviral.2019.04.001_bib43","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1086\/653621","article-title":"A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo","volume":"202","author":"Moscona","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.04.001_bib44","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1093\/infdis\/jis622","article-title":"A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection","volume":"206","author":"Moss","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.04.001_bib45","doi-asserted-by":"crossref","first-page":"6310","DOI":"10.1128\/JVI.75.14.6310-6320.2001","article-title":"A single amino acid alteration in the human parainfluenza virus type 3 hemagglutinin-neuraminidase glycoprotein confers resistance to the inhibitory effects of zanamivir on receptor binding and neuraminidase activity","volume":"75","author":"Murrell","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.04.001_bib46","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1465-9921-8-73","article-title":"Sialic acid receptor detection in the human respiratory tract: evidence for widespread distribution of potential binding sites for human and avian influenza viruses","volume":"8","author":"Nicholls","year":"2007","journal-title":"Respir. Res."},{"key":"10.1016\/j.antiviral.2019.04.001_bib47","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(00)02288-1","article-title":"Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial","volume":"355","author":"Nicholson","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2019.04.001_bib48","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1128\/JVI.00475-09","article-title":"Human parainfluenza virus infection of the airway epithelium: viral hemagglutinin-neuraminidase regulates fusion protein activation and modulates infectivity","volume":"83","author":"Palermo","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.04.001_bib49","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00235-16","article-title":"Features of circulating parainfluenza virus required for growth in human airway","volume":"7","author":"Palermo","year":"2016","journal-title":"mBio"},{"key":"10.1016\/j.antiviral.2019.04.001_bib50","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1021\/acschembio.8b00150","article-title":"Structural insights into human parainfluenza virus 3 hemagglutinin-neuraminidase using unsaturated 3- N-substituted sialic acids as probes","volume":"13","author":"Pascolutti","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.antiviral.2019.04.001_bib51","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1006\/viro.1999.0024","article-title":"The use of a quantitative fusion assay to evaluate HN\u2013receptor interaction for human parainfluenza virus type 3","volume":"265","author":"Perlman","year":"1999","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2019.04.001_bib52","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1128\/JVI.02617-06","article-title":"A second receptor binding site on human parainfluenza virus type 3 hemagglutinin-neuraminidase contributes to activation of the fusion mechanism","volume":"81","author":"Porotto","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.04.001_bib53","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1074\/jbc.M111.298059","article-title":"Mechanism of fusion triggering by human parainfluenza virus type III: communication between viral glycoproteins during entry","volume":"287","author":"Porotto","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2019.04.001_bib54","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1128\/JVI.77.6.3647-3654.2003","article-title":"Triggering of human parainfluenza virus 3 fusion protein (F) by the hemagglutinin-neuraminidase (HN) protein: an HN mutation diminishes the rate of F activation and fusion","volume":"77","author":"Porotto","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.04.001_bib55","doi-asserted-by":"crossref","first-page":"12446","DOI":"10.1128\/JVI.75.24.12446-12451.2001","article-title":"Contribution of the human parainfluenza virus type 3 HN-receptor interaction to pathogenesis in vivo","volume":"75","author":"Prince","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.04.001_bib56","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11262-013-0919-x","article-title":"Deletion of the D domain of the human parainfluenza virus type 3 (HPIV3) PD protein results in decreased viral RNA synthesis and beta interferon (IFN-beta) expression","volume":"47","author":"Roth","year":"2013","journal-title":"Virus Gene."},{"key":"10.1016\/j.antiviral.2019.04.001_bib57","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/ncomms1114","article-title":"Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase","volume":"1","author":"Rudrawar","year":"2010","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2019.04.001_bib58","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.1039\/c2ob25627d","article-title":"Synthesis and evaluation of novel 3-C-alkylated-Neu5Ac2en derivatives as probes of influenza virus sialidase 150-loop flexibility","volume":"10","author":"Rudrawar","year":"2012","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.antiviral.2019.04.001_bib59","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.bbmt.2016.02.011","article-title":"DAS181 for treatment of parainfluenza virus infections in hematopoietic stem cell transplant recipients at a single center","volume":"22","author":"Salvatore","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.antiviral.2019.04.001_bib60","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1586\/ers.11.32","article-title":"Progress in the development of human parainfluenza virus vaccines","volume":"5","author":"Schmidt","year":"2011","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.antiviral.2019.04.001_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028382","article-title":"The C proteins of human parainfluenza virus type 1 block IFN signaling by binding and retaining Stat1 in perinuclear aggregates at the late endosome","volume":"7","author":"Schomacker","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.04.001_bib62","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1093\/cid\/ciu134","article-title":"Parainfluenza virus lower respiratory tract disease after hematopoietic cell transplant: viral detection in the lung predicts outcome","volume":"58","author":"Seo","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.04.001_bib63","first-page":"809","article-title":"Antiviral drug resistance: mechanisms and clinical implications","volume":"24","author":"Strasfeld","year":"2010","journal-title":"Infect. Dis. Clin."},{"key":"10.1016\/j.antiviral.2019.04.001_bib64","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.antiviral.2015.08.014","article-title":"Catalytic mechanism and novel receptor binding sites of human parainfluenza virus type 3 hemagglutinin-neuraminidase (hPIV3 HN)","volume":"123","author":"Streltsov","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.04.001_bib65","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1128\/JVI.75.10.4604-4613.2001","article-title":"Receptor specificities of human respiroviruses","volume":"75","author":"Suzuki","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.04.001_bib66","doi-asserted-by":"crossref","first-page":"13028","DOI":"10.1128\/JVI.76.24.13028-13033.2002","article-title":"Role of the hemagglutinin-neuraminidase protein in the mechanism of paramyxovirus-cell membrane fusion","volume":"76","author":"Takimoto","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.04.001_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2006.03.016","article-title":"Antiviral effects of glycosylation and glucose trimming inhibitors on human parainfluenza virus type 3","volume":"72","author":"Tanaka","year":"2006","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.04.001_bib68","doi-asserted-by":"crossref","first-page":"8962","DOI":"10.1128\/JVI.00739-13","article-title":"Quantitative comparison of human parainfluenza virus hemagglutinin-neuraminidase receptor binding and receptor cleavage","volume":"87","author":"Tappert","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.04.001_bib69","doi-asserted-by":"crossref","first-page":"12146","DOI":"10.1128\/JVI.05537-11","article-title":"Fixation of oligosaccharides to a surface may increase the susceptibility to human parainfluenza virus 1, 2, or 3 hemagglutinin-neuraminidase","volume":"85","author":"Tappert","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.04.001_bib70","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S0959-440X(96)80014-5","article-title":"Sialidases: structures, biological significance and therapeutic potential","volume":"6","author":"Taylor","year":"1996","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.antiviral.2019.04.001_bib71","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1021\/jm00031a011","article-title":"Molecular modeling studies on ligand binding to sialidase from influenza virus and the mechanism of catalysis","volume":"37","author":"Taylor","year":"1994","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.04.001_bib72","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.bmcl.2006.12.105","article-title":"Synthesis and evaluation of 4-O-alkylated 2-deoxy-2, 3-didehydro-N-acetylneuraminic acid derivatives as inhibitors of human parainfluenza virus type-3 sialidase activity","volume":"17","author":"Tindal","year":"2007","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.antiviral.2019.04.001_bib73","doi-asserted-by":"crossref","first-page":"e7788","DOI":"10.1371\/journal.pone.0007788","article-title":"Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein","volume":"4","author":"Triana-Baltzer","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.04.001_bib74","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.bbmt.2012.04.012","article-title":"Human parainfluenza virus infection after hematopoietic stem cell transplantation: risk factors, management, mortality, and changes over time","volume":"18","author":"Ustun","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.antiviral.2019.04.001_bib75","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/ncomms2487","article-title":"Influenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitors","volume":"4","author":"Vavricka","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2019.04.001_bib76","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10719-006-5433-0","article-title":"Role of sialic acid-containing molecules in paramyxovirus entry into the host cell: a minireview","volume":"23","author":"Villar","year":"2006","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.antiviral.2019.04.001_bib77","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/363418a0","article-title":"Rational design of potent sialidase-based inhibitors of influenza virus replication","volume":"363","author":"von Itzstein","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2019.04.001_bib78","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1021\/cr4002879","article-title":"Fluorine in pharmaceutical industry: fluorine-containing drugs introduced to the market in the last decade (2001\u20132011)","volume":"114","author":"Wang","year":"2013","journal-title":"Chem. Rev."},{"key":"10.1016\/j.antiviral.2019.04.001_bib79","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1074\/jbc.M510677200","article-title":"Structural and kinetic analysis of two covalent sialosyl-enzyme intermediates on Trypanosoma rangeli sialidase","volume":"281","author":"Watts","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2019.04.001_bib80","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003534","article-title":"Structure of the parainfluenza virus 5 (PIV5) hemagglutinin-neuraminidase (HN) ectodomain","volume":"9","author":"Welch","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2019.04.001_bib81","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00006454-200102000-00002","article-title":"Oral oseltamivir treatment of influenza in children","volume":"20","author":"Whitley","year":"2001","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.antiviral.2019.04.001_bib82","doi-asserted-by":"crossref","first-page":"18447","DOI":"10.1021\/ja3084658","article-title":"Exposing the flexibility of human parainfluenza virus hemagglutinin-neuraminidase","volume":"134","author":"Winger","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.antiviral.2019.04.001_bib83","doi-asserted-by":"crossref","first-page":"e00803","DOI":"10.1128\/mBio.00803-13","article-title":"Interaction between the hemagglutinin-neuraminidase and fusion glycoproteins of human parainfluenza virus type III regulates viral growth in vivo","volume":"4","author":"Xu","year":"2013","journal-title":"mBio"},{"key":"10.1016\/j.antiviral.2019.04.001_bib84","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.4049\/jimmunol.128.6.2670","article-title":"Delineation of four antigenic sites on a paramyxovirus glycoprotein via which monoclonal antibodies mediate distinct antiviral activities","volume":"128","author":"Yewdell","year":"1982","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2019.04.001_bib85","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1128\/JVI.78.7.3733-3741.2004","article-title":"Second sialic acid binding site in Newcastle disease virus hemagglutinin-neuraminidase: implications for fusion","volume":"78","author":"Zaitsev","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.04.001_bib86","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.antiviral.2015.09.008","article-title":"Phase 1 clinical trials of DAS181, an inhaled sialidase, in healthy adults","volume":"123","author":"Zenilman","year":"2015","journal-title":"Antivir. Res."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421830740X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421830740X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:28:40Z","timestamp":1759062520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016635421830740X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":86,"alternative-id":["S016635421830740X"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.04.001","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New antiviral approaches for human parainfluenza: Inhibiting the haemagglutinin-neuraminidase","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}